Based in Berkeley, California, Kyverna was founded in 2018 by Chief Scientific Officer, Jeffrey Greve, Ph.D., and venture capitalists Fred Cohen and Beth Seidenberg. The company’s founding premise was that advances in cell engineering to create successful therapies for cancer could be applied to autoimmune disease, where there are a vast number of diseases that are not adequately treated by currently available therapies.
In January 2020, the company announced a $25M Series A investment from Vida Ventures, Westlake Partners, and Gilead. At this time, the company named industry veteran Dominic Borie, MD., Ph.D., an accomplished immunologist, digestive tract and liver transplant surgeon with extensive drug development experience from Genentech, Roche and Amgen, as the company’s Chief Executive Officer. Kyverna also announced it had entered into a strategic collaboration and license agreement with Gilead to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna’s synthetic regulatory T cell platform and synNotch technology from Kite, a Gilead company.
Kyverna’s overall goal is to make a significant and transformational impact to the lives of patients under the siege of autoimmune disease. This may be achieved through the use of select cell therapy approaches affording sustained therapeutic benefit from a single, or relatively few, infusion(s) and eliminating the need for chronic and suboptimal therapies.